FDA OKs Tesaro’s "Niraparib" For Ovarian Cancer - Major Setback For Myriad Genetics Inc

Tesaro, Inc. has been given a broad approval by the FDA for the use of its PARP drug niraparib, which will now be marketed as Zejula as a maintenance therapy for recurrent ovarian cancer which represents a major setback for Myriad Genetics, Inc.